Fedora Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fedora Pharmaceuticals Inc.
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Point-of-care diagnostics are back in favor with investors who believe market forces and technological advances are finally converging in ways that invite success and this time, they may be right. Profiles of GeneWEAVE, HiberGene, Spectromics, and Xagenic.
A solution to global antibiotics resistance will need co-ordination, focused drug innovation and the selective use of new medicines, in a manner not unlike that which turned HIV from a terminal illness into a chronic condition, participants at the Pharma Summit 2015 are told.